| Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers G Hripcsak, JD Duke, NH Shah, CG Reich, V Huser, MJ Schuemie, ... Studies in health technology and informatics 216, 574, 2015 | 1143 | 2015 |
| Validation of a common data model for active safety surveillance research JM Overhage, PB Ryan, CG Reich, AG Hartzema, PE Stang Journal of the American Medical Informatics Association 19 (1), 54-60, 2012 | 499 | 2012 |
| Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership PE Stang, PB Ryan, JA Racoosin, JM Overhage, AG Hartzema, C Reich, ... Annals of internal medicine 153 (9), 600-606, 2010 | 436 | 2010 |
| Novel data‐mining methodologies for adverse drug event discovery and analysis R Harpaz, W DuMouchel, NH Shah, D Madigan, P Ryan, C Friedman Clinical Pharmacology & Therapeutics 91 (6), 1010-1021, 2012 | 431 | 2012 |
| A harmonized data quality assessment terminology and framework for the secondary use of electronic health record data MG Kahn, TJ Callahan, J Barnard, AE Bauck, J Brown, BN Davidson, ... Egems 4 (1), 2016 | 400 | 2016 |
| Characterizing treatment pathways at scale using the OHDSI network G Hripcsak, PB Ryan, JD Duke, NH Shah, RW Park, V Huser, MA Suchard, ... Proceedings of the National Academy of Sciences 113 (27), 7329-7336, 2016 | 345 | 2016 |
| Performance of pharmacovigilance signal‐detection algorithms for the FDA adverse event reporting system R Harpaz, W DuMouchel, P LePendu, A Bauer‐Mehren, P Ryan, ... Clinical Pharmacology & Therapeutics 93 (6), 539-546, 2013 | 307 | 2013 |
| Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis MA Suchard, MJ Schuemie, HM Krumholz, SC You, RJ Chen, N Pratt, ... The Lancet 394 (10211), 1816-1826, 2019 | 302 | 2019 |
| Feasibility and utility of applications of the common data model to multiple, disparate observational health databases EA Voss, R Makadia, A Matcho, Q Ma, C Knoll, M Schuemie, FJ DeFalco, ... Journal of the American Medical Informatics Association 22 (3), 553-564, 2015 | 265 | 2015 |
| Interpreting observational studies: why empirical calibration is needed to correct p‐values MJ Schuemie, PB Ryan, W DuMouchel, MA Suchard, D Madigan Statistics in medicine 33 (2), 209-218, 2014 | 219 | 2014 |
| Feasibility of using real-world data to replicate clinical trial evidence VL Bartlett, SS Dhruva, ND Shah, P Ryan, JS Ross JAMA network open 2 (10), e1912869-e1912869, 2019 | 213 | 2019 |
| Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non‐SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 … PB Ryan, JB Buse, MJ Schuemie, F DeFalco, Z Yuan, PE Stang, JA Berlin, ... Diabetes, Obesity and Metabolism 20 (11), 2585-2597, 2018 | 205 | 2018 |
| Evaluating the impact of database heterogeneity on observational study results D Madigan, PB Ryan, M Schuemie, PE Stang, JM Overhage, ... American journal of epidemiology 178 (4), 645-651, 2013 | 204 | 2013 |
| A curated and standardized adverse drug event resource to accelerate drug safety research JM Banda, L Evans, RS Vanguri, NP Tatonetti, PB Ryan, NH Shah Scientific data 3 (1), 1-11, 2016 | 200 | 2016 |
| Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership PB Ryan, D Madigan, PE Stang, J Marc Overhage, JA Racoosin, ... Statistics in medicine 31 (30), 4401-4415, 2012 | 192 | 2012 |
| Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data JM Reps, MJ Schuemie, MA Suchard, PB Ryan, PR Rijnbeek Journal of the American Medical Informatics Association 25 (8), 969-975, 2018 | 182 | 2018 |
| Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled … JCE Lane, J Weaver, K Kostka, T Duarte-Salles, MTF Abrahao, H Alghoul, ... MedRxiv, 2020 | 178 | 2020 |
| Challenges with quality of race and ethnicity data in observational databases FCG Polubriaginof, P Ryan, H Salmasian, AW Shapiro, A Perotte, ... Journal of the American Medical Informatics Association 26 (8-9), 730-736, 2019 | 153 | 2019 |
| Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study X Li, A Ostropolets, R Makadia, A Shoaibi, G Rao, AG Sena, ... bmj 373, 2021 | 150 | 2021 |
| Renin–angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis DR Morales, MM Conover, SC You, N Pratt, K Kostka, T Duarte-Salles, ... The Lancet Digital Health 3 (2), e98-e114, 2021 | 146 | 2021 |
Martijn SchuemieJanssen R&D在 ohdsi.org 的电子邮件经过验证
